Recent Updates
Recently added Catalysts

Perillyl alcohol

Phase 1

Glioblastoma Multiforme | Small molecule | Oncology |NeOnc Technologies Holdings, Inc.|Last Updated: Jul 16, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
CONTROLLEDDMC
Total Trials1
Total Enrollment49
FDA Designations
No designations recorded
Clinical trial landscape

Perillyl alcohol · 1 trial · 1 indication

Phase 1 1
NCT02704858Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaGlioblastoma Multiforme
ACTIVE NOT_RECRUITING49 Analytics
PHASE1ACTIVE NOT_RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Glioblastoma Multiforme
NCT0270485849
Unlock trial analytics
Study Endpoints
Primary Endpoints
Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Up to 6 months
Phase 2 Primary Outcome: Number of Participants Who Are Alive Each Month For 6 Months
Up to 6 months
Phase 2 Primary Outcome: Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related To Treatment
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
NEO100 Phase 1EXPERIMENTALIntranasal delivery of NEO100 (perillyl alcohol) four times a day, escalation up to four different doses to determine maximum tolerated dose.
NEO100 Phase 2AEXPERIMENTALIntranasal delivery of NEO100 (perillyl alcohol) four times a day. Treatment of total of 25 patients at maximum tolerated dose.
Interventions
NameTypeDescription
Perillyl alcoholDRUGIntranasal administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria To be eligible to participate in the study, a patient must meet all of the following inclusion criteria: * Patient must have radiographically-confirmed progression of, or recurrent, primary or secondary Grade IV glioma, including infratentorial (brainstem, cerebellar) glioma (co...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMJul 17, 2026NCT02704858Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJul 17, 2026NCT02704858Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJul 17, 2026NCT02704858Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 26, 2026NCT02704858primaryCompletionDate: changed
LOWMay 24, 2026NCT02704858studyFirstPostDate: changed